A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients With Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet

This study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).

Start Date24 Aug 2020

Sponsor / Collaborator

Provention Bio, Inc.

NCT02633020

/ CompletedPhase 2

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma

Protocol CELIM-RCD-002 is designed to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with type II refractory celiac disease (RCD-II), an in-situ small bowel T-cell lymphoma.

Start Date13 Apr 2016

Sponsor / Collaborator

Amgen, Inc.

100 Clinical Results associated with Ordesekimab

100 Translational Medicine associated with Ordesekimab

100 Patents (Medical) associated with Ordesekimab

Literatures (Medical) associated with Ordesekimab

05 May 2025·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Comparative Efficacy of Interleukin-7 and -15 Blockade in Alleviating Experimental Chronic Uveitis and Suppressing Pathogenic Memory CD4⁺ T Cells

Article

Author: Shayan, Maryam ; Chen, Yihe ; Zhu, Qiurong ; Huckfeldt, Rachel M.

Purpose:

We have previously demonstrated the pathogenic function of memory CD4+ T cells, which express IL-7 receptor (IL-7R) and IL-15R, in experimental chronic autoimmune uveitis (CAU). Here, we aimed to compare the therapeutic efficacy of blocking IL-7 or IL-15 in CAU.

Methods:

C57BL/6J mice were induced for CAU, then intraperitoneally injected with an anti-IL-7 antibody (Ab), an anti-IL-15 Ab, or an IgG control for 2 weeks. Disease was evaluated by weekly fundoscopy, optical coherence tomography (OCT), and full-field electroretinography for four weeks from the initiation of treatment. At week 4, retina and cervical lymph nodes (CLN) were collected for flow cytometry analysis of T-cell response.

Results:

The anti-IL-7 Ab led to progressively reduced retinal infiltration and structural damage, with rapid recovery of retinal function. The anti-IL-15 Ab resulted in moderately reduced retinal infiltration and structural damage, along with a delayed, partial functional improvement. Compared to the control group, the anti-IL-7 Ab group exhibited significantly reduced disease scores from baseline on fundoscopy and OCT at week 4, and substantially improved dark-adapted (DA) a-wave and light-adapted b-wave responses at week 2; although the anti-IL-15 Ab group showed significantly improved disease from baseline only on OCT and increased DA b-waves at week 4. Both treatments effectively depleted the retinal infiltrating T cells and reduced memory Th17 cells in the CLN.

Conclusions:

Our proof-of-concept study demonstrates that blocking IL-7 or IL-15 leads to specific depletion of the uveitogenic memory CD4+ T cells and disruption of disease chronicity in uveitis.

31 Dec 2022·Journal of immunotoxicology

Strategies to evaluate potential effector function of glycan variants: A case study of ordesekimab (AMG 714 or PRV-015)

Review

Author: Werner, Jonathan ; Kuhns, Scott ; Lebrec, Hervé ; Wegesser, Teresa ; Wang, Xiaoting ; Wei, Yu-Ling

The potential for effector functions of therapeutic antibodies, including antibody-dependent cell-mediated cytotoxicity (ADCC), is a biological activity of interest for characterization, regardless of if ADCC is an intended primary pharmacological effect. The composition of the conserved antibody F_c glycan can vary as a function of post-translational processing which may affect the binding affinity to F_c receptors, leading to a change of effector activity. Ordesekimab (AMG 714 or PRV-015), a fully human immunoglobulin G₁-kappa anti-interleukin (IL)-15 monoclonal antibody, is in clinical development for celiac disease. The binding of ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Therefore, the simultaneous binding of ordesekimab to the F_cγ receptor (R) IIIα expressed on natural killer (NK) cells and to the IL-15/IL-15Rα complex on cells such as monocytes may theoretically enable ADCC toward the IL-15Rα-expressing cells. The high mannose (HM) levels on the F_c glycan were found to vary in different lots of ordesekimab resulting from refinements to the manufacturing process, and the impact on ordesekimab-mediated ADCC activity was evaluated in in vivo and in vitro studies. A review of nonclinical and clinical data found no evidence of ordesekimab-induced depletion of monocytes, or cytotoxicity in organs with wide IL-15Rα expression, suggesting a lack of in vivo ADCC activity. In addition, in vitro peripheral blood mononuclear cells-based ADCC assay did not reveal any cytolytic effect of ordesekimab with various levels of HM content when cocultured with recombinant human IL-15. Taken together, these data demonstrate that ADCC is not a potential liability for ordesekimab and does not contribute to the reduction of IL-15-mediated inflammation, the intended pharmacological effect.

01 Dec 2019·The lancet. Gastroenterology & hepatologyQ1 · MEDICINE

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Q1 · MEDICINE

Article

Author: Samuli Rounioja ; Nadine Cerf-Bensussan ; Ashleigh Palmer ; David Sanders ; Sheila E Crowe ; Georgia Malamut ; Knut EA Lundin ; Valerie Byrnes ; Peter H R Green ; George Vlad ; Tom van Gils ; Sherine Khater ; Joseph Murray ; Raquel Perez Maseda ; Anne Blanchard ; Garbiñe Roy Ariño ; Jane R Parnes ; Laura Crespo ; Keijo Viiri ; Michel Azizi ; Carlota García-Hoz ; Amelie Trinquand ; Chris J Mulder ; Anthony DiMarino ; Elizabeth Macintyre ; Olivier Hermine ; Pekka Collin ; Beth Llewellyn ; Govind Bhagat ; Michael Schumann ; Christophe Cellier ; Marios Hadjivassiliou ; Hetty Bontkes ; Bertrand Meresse ; Ralph Raymond ; Wayne Tsuji ; Gerd Bouma ; Ciaran P Kelly ; Francisco Leon ; Eric Butz ; Jack Bui ; Bana Jabri

BACKGROUND:

Refractory coeliac disease type 2 is a rare subtype of coeliac disease with high mortality rates; interleukin 15 (IL-15) is strongly implicated in its pathophysiology. This trial aimed to investigate the effects of AMG 714, an anti-IL-15 monoclonal antibody, on the activity and symptoms of refractory coeliac disease type 2.

METHODS:

This was a randomised, double-blind, placebo-controlled, phase 2a study of adults with a confirmed diagnosis of refractory coeliac disease type 2. Patients were randomly assigned at a 2:1 ratio to receive seven intravenous doses over 10 weeks of AMG 714 (8 mg/kg) or matching placebo. Biopsy samples were obtained at baseline and week 12 for cellular analysis and histology. The change in the proportion of aberrant intraepithelial lymphocytes from baseline to week 12 with respect to all intraepithelial lymphocytes was the primary endpoint and was quantified using flow cytometry. Secondary endpoints were the change in aberrant intraepithelial lymphocytes with respect to intestinal epithelial cells; intestinal histological scores (villous height-to-crypt depth ratio; VHCD); intraepithelial lymphocyte counts; Marsh score; and patient-reported symptom measures, including the Bristol stool form scale (BSFS) and gastrointestinal symptom rating scale (GSRS). Main analyses were done in the per-protocol population of patients who received their assigned treatment, provided evaluable biopsy samples, and did not have major protocol deviations; only patients with non-atypical disease were included in the analyses of aberrant intraepithelial lymphocytes, including the primary analysis. Safety was assessed in all patients who received at least one dose of study drug. This study is registered at ClinicalTrials.gov (NCT02633020) and EudraCT (2015-004063-36).

FINDINGS:

From April 13, 2016, to Jan 19, 2017, 28 patients were enrolled and randomly assigned to AMG 714 (n=19) and placebo (n=9). Six patients were not included in the primary analysis because of protocol deviation (one in the AMG 714 group), insufficient biopsy samples (one in the AMG 714 group), and atypical intraepithelial lymphocytes (three in the AMG 714 group and one in the placebo group). At 12 weeks, the least square mean difference between AMG 714 and placebo in the relative change from baseline in aberrant intraepithelial lymphocyte percentage was -4·85% (90% CI -30·26 to 20·56; p=0·75). The difference between the AMG 714 and placebo groups in aberrant intraepithelial lymphocytes with respect to epithelial cells at 12 weeks was -38·22% (90% CI -95·73 to 19·29; nominal p=0·18); the difference in change in Marsh score from baseline was 0·09% (95% CI -1·60-1·90; nominal p=0·92); the difference in VHCD ratio was 10·67% (95% CI -38·97 to 60·31; nominal p=0·66); and the difference in change in total intraepithelial lymphocyte count was -12·73% (95% CI -77·57-52·12); nominal p=0·69). Regarding symptoms, the proportion of patients with diarrhoea per the BSFS score decreased from ten (53%) of 19 at baseline to seven (37%) of 19 at week 12 in the AMG 714 group and increased from two (22%) of nine at baseline to four (44%) of nine at week 12 in the placebo group (nominal p=0·0008); and the difference between the groups in change in GSRS score was -0·14 (SE 0·19; nominal p=0·48). Eight (89%) patients in the placebo group and 17 (89%) in the AMG 714 group had treatment-emergent adverse events, including one (11%) patient in the placebo group and five (26%) in the AMG 714 group who had serious adverse events. The most common adverse event in the AMG 714 group was nasopharyngitis (eight [42%] patients vs one [11%] in the placebo group).

INTERPRETATION:

In patients with refractory coeliac disease type 2 who were treated with AMG 714 or placebo for 10 weeks, there was no difference between the groups in terms of the primary endpoint of aberrant intraepithelial lymphocyte reduction from baseline. Effects on symptoms and other endpoints suggest that further research of AMG 714 may be warranted in patients with refractory coeliac disease type 2.

FUNDING:

Celimmune and Amgen.

News (Medical) associated with Ordesekimab

02 Sep 2026

·www.fiercebiotech.com

Teva autoimmune antibody notches ph. 2 win in celiac disease

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac disease. In a phase 2a trial of 50 adults with celiac disease, patients received a dose of either TEV ‘408 or placebo and then, two weeks later, began eating gluten every day for six weeks. TEV ‘408 reduced the amount of intestinal damage caused by gluten significantly more than placebo, Teva reported today, hitting the trial’s primary endpoint. Teva has observed no safety signals associated with the antibody, according to the release. “These results underscore the potential to move beyond managing gluten exposure and address celiac disease at its biological source,” Eric Hughes, M.D., Ph.D., Teva’s chief medical officer and head of global R&D, said in the release. “They also strengthen our confidence in targeting the IL-15 pathway as an approach to reducing immune-driven intestinal damage.” More dose-ranging and analysis of the phase 2 data are needed before a phase 3 follow-up can proceed, a Teva spokesperson told Fierce. “The celiac timeline remains subject to clinical results and regulatory alignment,” the spokesperson said. “Celiac remains a priority and will progress as quickly as possible.” Teva is also testing the antibody in the skin disease vitiligo, with plans to launch a phase 2b trial in the indication later this year. Royalty Pharma agreed earlier this year to help fund the trial and a potential phase 3 follow-up with up to $500 million in exchange for a share of the vitiligo sales haul, should TEV ‘408 be approved. There are currently no approved drugs that inhibit IL-15, a proinflammatory protein. Other similar antibodies are in the works from Novartis (picked up from Calypso Biotech in 2024) and argenx (from this summer’s $2.2 billion buy of Forte Biosciences ). Novartis’ prospect targets IL-15 alone, like TEV ‘408, while argenx’s option also hits interleukin-2 by targeting CD122. Comparing these different antibodies is currently unwise, Umer Raffat, a biotech industry analyst with Evercore ISI, cautioned in a note to investors today. That said, Teva’s data is good but unsurprising, he wrote, and the company “identified a potentially optimal dose.” The expected nature of the result—given other anti-IL-15 antibodies have also shown activity in celiac disease—may explain the lack of movement in Teva’s stock this morning. “Teva’s R&D turnaround keeps getting better and continues to bode well for continued stock upside,” Raffat added. Teva considers TEV ‘408 a potential “pipeline in a product,” but has not yet revealed plans beyond celiac disease and vitiligo. “There’s broad relevance across high-prevalence autoimmune diseases in gastroenterology, dermatology and rheumatology,” the Teva spokesperson told Fierce. The pharma has been operating with a growth mindset as of late, recently agreeing to scoop up bankrupt BioXcel Therapeutics’ assets for $57.5 million upfront and bringing in $400 million from Blackstone Life Sciences to power development of a Sanofi-partnered anti-TL1A antibody for inflammatory bowel disease.

12 Jan 2026

·www.fiercebiotech.com

Teva lines up $500M in Royalty Pharma funding for vitiligo drug

If Royalty Pharma is happy with the results of Teva\'s phase 2b vitiligo study, the company has the option to hand over the remaining $425 million.\n Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development of a drug for vitiligo.The deal centers around TEV-‘408, an anti-IL-15 antibody that is currently in a phase 2 study for celiac disease as well as a phase 1b trial for vitiligo. Both studies are set to read out this year.In the Jan. 11 release, Teva pointed to emerging information from the vitiligo study it claimed “provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions.”The deal with Royalty will see the financing company potentially hand $500 million to fund the development of TEV-‘408 for vitiligo specifically. The first tranche of $75 million will be used to bankroll the launch of a phase 2b study in the indication this year.The only FDA-approved treatment for vitiligo, a chronic condition where skin loses pigment, is Incyte’s JAK inhibitor Opzelura. Attempts to develop new drugs for the condition ran into trouble last year, with both Incyte and Vyne Therapeutics scrapping their own candidates.Teva’s theory is that by blocking IL-15 activity, TEV-‘408 can reduce the immune-mediated destruction of pigment-producing cells called melanocytes, which otherwise results in white patches on the skin characteristic of vitiligo.If Royalty is happy with the results of the phase 2b vitiligo study, the company has the option to hand over the remaining $425 million, which would fund phase 3 development.In return, Teva will make a milestone payment to Royalty if the drug makes it to market, followed by royalties on worldwide net sales. The companies didn’t offer a breakdown of these financials. Royalty financing has gained popularity lately as traditional fundraising becomes increasingly difficult amid an overall biotech market cooldown. Teva’s previous agreement with Royalty dates back to 2023, when the Israeli company secured $100 million in funding to support the clinical development of olanzapine LAI, a long-acting version of Eli Lilly’s schizophrenia drug Zyprexa.As with that deal, Teva put its new agreement with Royalty deal in the context of the drugmaker’s “pivot to growth” strategy to accelerate its innovative pipeline and bring treatments to patients faster.“This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide,” Teva CEO Richard Francis said in yesterday\'s release. “Vitiligo represents a significant unmet need, with only one approved topical treatment currently available and no systemic options.”Royalty Pharma CEO Pablo Legorreta said the company’s continued collaboration with Teva “underscores Royalty Pharma’s role as a long-term, trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.”

Phase 2Drug ApprovalLicense out/in

27 May 2025

·www.einpresswire.com

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease Candidate demonstrates Teva’s commitment to bringing important new treatment options to underserved patient populations TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease. Fast Track is an FDA process designed to facilitate development and expedite review of drugs to treat serious conditions and address unmet medical needs. “The FDA’s decision to grant Fast Track designation for TEV-53408, an investigational anti-IL-15 antibody therapy, reflects the promising nature of the treatment and the urgent unmet need of people living with celiac disease,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “Teva is driven by a commitment to innovation and this latest achievement gets us one step closer to providing promising, innovative treatment options for patients with chronic autoimmune diseases like celiac disease.” TEV-53408 is an antibody designed to inhibit the activity of the cytokine, interleukin-15 (IL-15), to prevent intestinal damage and associated symptoms in individuals with celiac disease. This potential treatment is a testament to the growing strength of Teva’s innovative pipeline and dedication to advancing treatments for immunological conditions, including celiac disease, which affects approximately 1% of the global population. 1 -3 About TEV-53408 TEV-53408 is an investigational monoclonal antibody that inhibits interleukin-15 (IL-15), which aims to reduce the immune response to gluten that causes intestinal inflammation and damage in individuals with celiac disease. A Phase 2a study investigating the efficacy and safety of anti-IL-15 in adults with celiac disease is ongoing ( NCT06807463 ). About Celiac Disease Celiac disease is a chronic autoimmune disorder triggered by gluten, affecting the small intestine and leading to a range of symptoms. It can significantly impact an individual's quality of life, and diagnosis can be challenging. A strict, lifelong gluten-free diet is the only current treatment and even if adhering to a gluten-free diet, a significant proportion of patients still experience debilitating symptoms. In addition, trace amounts of gluten - especially through accidental or inadvertent ingestion - can cause severe reactions. Teva is dedicated to developing innovative medicines for immunological diseases, including celiac disease, with the goal of providing better health for people suffering from celiac disease worldwide. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to achieve expected results from investments in our product pipeline including to successfully develop and commercialize our anti-IL 15 (TEV-53408) asset for the treatment of people with celiac disease on a gluten-free diet; the risk that we will incur significant costs in connection with the development of anti-IL 15 (TEV-53408), which may exceed any revenue generated by anti-IL 15 (TEV-53408); risks that regulatory approvals and other requirements may delay the development and commercialization of our anti-IL 15 (TEV-53408); our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. References Gatti S, Rubio-Tapia A, Makharia G, Catassi C. Patient and Community Health Global Burden in a World with More Celiac Disease. Gastroenterology. 2024;167(1):23-33. Singh, Prashant et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018; 16(6), 823 - 836.e2 Mustalahti, K., Catassi, C., Reunanen, A., Fabiani, E., Heier, M., … McMillan, S. (2010). The prevalence of celiac disease in Europe: Results of a centralized, international mass screening project. Annals of Medicine , 2010; 42 (8), 587–595. Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquires TevaIR@Tevapharm.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Fast TrackImmunotherapy

100 Deals associated with Ordesekimab

External Link

KEGG	Wiki	ATC	Drug Bank
D12306	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Vitiligo	Phase 2	United States	Amgen, Inc.	11 Dec 2020
Celiac Disease	Phase 2	United States	Provention Bio, Inc.	24 Aug 2020
Celiac Disease	Phase 2	Canada	Provention Bio, Inc.	24 Aug 2020
Celiac Disease	Phase 2	Netherlands	Provention Bio, Inc.	24 Aug 2020
Celiac Disease	Phase 2	Spain	Provention Bio, Inc.	24 Aug 2020
Advanced Marginal Zone Lymphoma	Phase 2	United States	Amgen, Inc.	13 Apr 2016
Advanced Marginal Zone Lymphoma	Phase 2	Finland	Amgen, Inc.	13 Apr 2016
Advanced Marginal Zone Lymphoma	Phase 2	France	Amgen, Inc.	13 Apr 2016
Advanced Marginal Zone Lymphoma	Phase 2	Netherlands	Amgen, Inc.	13 Apr 2016
Advanced Marginal Zone Lymphoma	Phase 2	Spain	Amgen, Inc.	13 Apr 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04338581 (REVEAL, CTgov)	Phase 2	Vitiligo	60	nbUVB phototherapy+AMG 714 (AMG 714)	bphxxqzukq = kqfmqqktcy pjdibmmzuw (frafjrzrph, jvanfjvynf - dltfrqeiiv) View more	-	17 Nov 2025
				nbUVB phototherapy (Placebo)	bphxxqzukq = vnojfstabl pjdibmmzuw (frafjrzrph, aourqooqdj - swtlivmoji) View more
NCT04424927 (PROACTIVE, CTgov)	Phase 2	Celiac Disease	388	Placebo	vzyoguljjv(mikojpizaq) = aoofyvihqj qmebkoqodg (lixwspxzze, picnghiqhe - msobnpbaft) View more	-	20 Oct 2025
NCT02637141 (PRNewswire) Manual	Phase 2	Celiac Disease	-	Ordesekimab	fjfvmthpgj(xoekipzuoj) = did not meet primary or secondary endpoints. bmwngrtbyx (omjahdtafj ) Not Met View more	Negative	04 Feb 2025
				Placebo
UEGW2022	Phase 2	Refractory sprue aberrant intraepithelial lymphocytes (IEL)	28	AMG-714	zlhbskppsg(xiqmodiyim) = One of them developed enteropathy-associated T-cell lymphoma (EATL) and died dfoijbvusy (daobatgyik ) View more	Positive	09 Oct 2022
NCT02633020 (CTgov)	Phase 2	Advanced Marginal Zone Lymphoma \| Refractory sprue	28	AMG 714 (AMG 714)	iyeyboawzf(wudwmzonxe) = hqhjjakfml ipgkoksudf (wwkxxxvjtb, 8.83) View more	-	27 Dec 2019
				Placebo (Placebo)	iyeyboawzf(wudwmzonxe) = rebnwwecdq ipgkoksudf (wwkxxxvjtb, 11.70) View more
NCT02637141 (CTgov)	Phase 2	Celiac Disease	64	Placebo Gluten Challenge+AMG 714 (AMG 714 150 mg)	pndbekmfhz(hdrwkuwwlj) = nwgybsggpt wtwaezotgw (xirrilohnj, 5.39) View more	-	03 Dec 2019
				Placebo Gluten Challenge+AMG 714 (AMG 714 300 mg)	pndbekmfhz(hdrwkuwwlj) = lopgfbsmzb wtwaezotgw (xirrilohnj, 4.83) View more
EULAR2006	Phase 2	Rheumatoid Arthritis	180	AMG 714 280 mg	qnxwavztyt(qreouqxllr) = tgrnrvngsw tensrjwcsn (jcviwzhaqq )	Positive	21 Jun 2006
				Placebo	qnxwavztyt(qreouqxllr) = nhrddozbev tensrjwcsn (jcviwzhaqq )
EULAR2003	Phase 1/2	Rheumatoid Arthritis	-	HuMax-IL15	wmqrytspmo(ecjvkeyivz) = uddclvfcwe dvdfgagyaz (zgjgxesvdu ) View more	-	18 Jun 2003

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis